Literature DB >> 2473324

Vascular mechanism of action of endothelin-1: effect of Ca2+ antagonists.

P E Chabrier1, M Auguet, P Roubert, M O Lonchampt, V Gillard, J M Guillon, S Delaflotte, P Braquet.   

Abstract

The vasoconstrictive properties of the endothelium-derived peptide, endothelin-1 (ET-1), were investigated on rat isolated aorta and on cultured rat aortic smooth muscle cells. In rat isolated aorta, endothelin-1 induced a slow and sustained contraction in a Ca2+-free medium; after calcium readmission, an additional sustained contraction was elicited. In vascular smooth muscle cells, endothelin-1 provoked a dose-dependent Ca2+ influx that was not inhibited by calcium entry blockers (nifedipine, D 600, or diltiazem). In these cells, [125I]-endothelin-1 bound to a specific, saturable, and high affinity recognition site (Kd about 10(-9) M and Bmax = 52 +/- 2 fmol/10(6) cells). The binding was not reversible and not affected by calcium antagonists. These data do not support the hypothesis that endothelin-1 acts as an endogenous agonist of the voltage-dependent Ca2+ channels. The action of endothelin-1 can be separated into two components: one dependent on Ca2+ influx but insensitive to calcium antagonists and another independent of extracellular Ca2+. The irreversible binding of endothelin-1 may reflect an internalization of the ligand inside the cell membrane, leading to multiple contractile events.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473324     DOI: 10.1097/00005344-198900135-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Effect of cromakalim (BRL 34915) on hemodynamic and electrocardiographic changes induced by endothelin in dogs.

Authors:  T Tsunetoshi; A Otsuka; H Mikami; K Katahira; A Moriguchi; T Ogihara
Journal:  Basic Res Cardiol       Date:  1991 Jan-Feb       Impact factor: 17.165

2.  Pharmacological characterization of Ca2+ entry channels in endothelin-1-induced contraction of rat aorta using LOE 908 and SK&F 96365.

Authors:  X F Zhang; Y Iwamuro; T Enoki; M Okazawa; K Lee; T Komuro; T Minowa; Y Okamoto; H Hasegawa; H Furutani; S Miwa; T Masaki
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells.

Authors:  T E Bunchman; C A Brookshire
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Endothelin-1-induced constriction in the coronary resistance vessels and abdominal aorta of the guinea pig.

Authors:  A Folta; I G Joshua; R C Webb
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

5.  Endothelin-1 mRNA is widely expressed in porcine and human tissues.

Authors:  D J Nunez; M J Brown; A P Davenport; C B Neylon; J P Schofield; R K Wyse
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  The effect of diltiazem on the coronary haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin-1 in the anaesthetized dog.

Authors:  A J Nichols; P F Koster; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

7.  Cholesterol depletion alters coronary artery myocyte Ca(2+) signalling in a stimulus-specific manner.

Authors:  Clodagh Prendergast; John Quayle; Theodor Burdyga; Susan Wray
Journal:  Cell Calcium       Date:  2010-01       Impact factor: 6.817

8.  Participation of protein kinase C in endothelin-1-induced contraction in rat aorta: studies with a new tool, calphostin C.

Authors:  H Shimamoto; Y Shimamoto; C Y Kwan; E E Daniel
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

9.  Long-lasting activation of cation current by low concentration of endothelin-1 in mouse fibroblasts and smooth muscle cells of rabbit aorta.

Authors:  T Enoki; S Miwa; A Sakamoto; T Minowa; T Komuro; S Kobayashi; H Ninomiya; T Masaki
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.